Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores

Carrie A. Sailer, Spotswood L. Spruance, Christopher M. Hull

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese™[US], Xerclear®[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalVirus Adaptation and Treatment
Issue number1
StatePublished - 2011
Externally publishedYes


  • Acyclovir
  • HSV
  • Herpes labialis
  • Herpes simplex virus
  • Hydrocortisone
  • ME-609
  • Xerclear
  • Xerese

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases


Dive into the research topics of 'Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores'. Together they form a unique fingerprint.

Cite this